{"organizations": [], "uuid": "d7bea13efebdde0fbd3e8036445f9d4108a7ed9b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-transgene-q1-operating-revenue-sta/brief-transgene-q1-operating-revenue-stable-at-1-8-million-euros-idUSFWN1S31IQ", "country": "US", "domain_rank": 408, "title": "Transgene Q1 Operating Revenue Stable At 1.8 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.191, "site_type": "news", "published": "2018-04-27T00:40:00.000+03:00", "replies_count": 0, "uuid": "d7bea13efebdde0fbd3e8036445f9d4108a7ed9b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-transgene-q1-operating-revenue-sta/brief-transgene-q1-operating-revenue-stable-at-1-8-million-euros-idUSFWN1S31IQ", "ord_in_thread": 0, "title": "Transgene Q1 Operating Revenue Stable At 1.8 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Transgene SA:\n* TRANSGENE: â‚¬35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018\n* CLINICAL TRIALS NOW ON-GOING WITH 5 IMMUNO-THERAPEUTICS\n* CLINICAL READOUTS EXPECTED FOR EACH OF OUR 5 PRODUCTS IN 2018\n* Q1 OPERATING REVENUE EUR 1.8 MILLION VERSUS EUR 1.9 MILLION YEAR AGO\n* TRANSGENE EXPECTS ITS CASH BURN FOR 2018 TO BE COMPARABLE TO 2017\n* TRANSGENE CONFIRMS THAT IT EXPECTS READOUTS IN 2018 FOR EACH OF ITS 5 PRODUCTS IN CLINICAL DEVELOPMENT Source text for Eikon: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T00:40:00.000+03:00", "crawled": "2018-04-27T16:36:55.019+03:00", "highlightTitle": ""}